Another Astellas Gene Therapy Deal, This Time $50M for Option on AviadoBio Dementia Program
Astellas Pharma is spreading its bets in neurodegenerative disorders, committing $50 million to AviadoBio for the opportunity to license its lead program, an experimental gene therapy for a type of dementia with no FDA-approved drugs. The sum breaks down …